CHARLOTTESVILLE, Va. – Drug maker AstraZeneca has come underneath scrutiny for its COVID-19 vaccine. Whereas it’s not approved for use in the United States, stories connecting it to a small variety of uncommon blood clots in Europe have raised issues throughout the globe.
“The protection concern is that there is been a really low incident of blood clots in sufferers which have obtained […] the AstraZeneca vaccine,” mentioned College of Virginia infectious illness knowledgeable Dr. William Petri. “It is one particular type of clot, which makes one involved about whether or not that could possibly be a aspect impact since it isn’t your on a regular basis blood clot.”
Dr. Petri mentioned the incidence of this one type of blood clot is not any completely different in individuals who received the vaccine than can be anticipated within the inhabitants normally. In accordance with AstraZeneca, 40 individuals out of the 17 million who obtained their vaccine developed blood clots. The AstraZeneca vaccine was sidelined in almost a dozen international locations in Europe, together with Germany, France and Italy, over fears of a causal relationship between the vaccine and blood cloths.
The FDA has not given emergency use authorization for the AstraZeneca vaccine in the USA however Dr. Petri mentioned the U.S. might attain herd immunity with the at present accredited Pfizer, Moderna and Johnson & Johnson vaccines.